Stoke Therapeutics, Inc.
DE ˙ DB ˙ US86150R1077
24,23 € ↓ -0,45 (-1,82%)
2026-06-05
DEL PRIS
SecurityDE:0GT / Stoke Therapeutics, Inc.
InstitutionJpmorgan Chase & Co
Latest Disclosed Ownership265,473 shares
Latest Disclosed Value $ 8,434,078
Jpmorgan Chase & Co ownership in 0GT / Stoke Therapeutics, Inc.

On May 13, 2026 - Jpmorgan Chase & Co filed a 13F-HR/A form disclosing ownership of 265,473 shares of Stoke Therapeutics, Inc. (DE:0GT) valued at $7,273,960 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 277,930 shares of Stoke Therapeutics, Inc.. This represents a change in shares of -4.48% during the quarter. The current value of the position is $6,432,411 USD.

Jpmorgan Chase & Co has a history of taking positions in derivatives of the underlying security (0GT) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:0GT / Stoke Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F/A-1 STOKE THERAPEUTICS COMMON 86150R107 265,473 -12,457 -4.48 8,434 -4.39 0.0001
2026-02-11 2025-12-31 13F STOKE THERAPEUTICS COMMON 86150R107 277,930 253,554 1,040.18 8,821 1,442.13 0.0006
2025-11-26 2025-09-30 13F/A-1 STOKE THERAPEUTICS COMMON 86150R107 24,376 -1,279 -4.99 573 96.56 0.0000
2025-11-07 2025-09-30 13F STOKE THERAPEUTICS COMMON 86150R107 24,376 -1,279 573 0.0000
2025-08-12 2025-06-30 13F STOKE THERAPEUTICS COMMON 86150R107 25,655 5,398 26.65 291 117.16 0.0000
2025-05-12 2025-03-31 13F STOKE THERAPEUTICS COMMON 86150R107 20,257 293 1.47 135 -39.09 0.0000
2025-02-12 2024-12-31 13F STOKE THERAPEUTICS COMMON 86150R107 19,964 4,512 29.20 220 16.40 0.0000
2024-12-26 2024-09-30 13F/A-1 STOKE THERAPEUTICS COMMON 86150R107 15,452 199 1.30 190 -8.25 0.0000
2024-11-08 2024-09-30 13F STOKE THERAPEUTICS COMMON 86150R107 15,452 199 190 0.0000
2024-12-26 2024-06-30 13F/A-1 STOKE THERAPEUTICS COMMON 86150R107 15,253 4,309 39.37 206 40.14 0.0000
2024-08-12 2024-06-30 13F STOKE THERAPEUTICS COMMON 86150R107 15,253 4,309 206 0.0000
2024-12-26 2024-03-31 13F/A-1 STOKE THERAPEUTICS COMMON 86150R107 10,944 -7,189 -39.65 148 54.74 0.0000
2024-05-10 2024-03-31 13F STOKE THERAPEUTICS COMMON 86150R107 10,944 -7,189 148 0.0000
2024-12-26 2023-12-31 13F/A-1 STOKE THERAPEUTICS COMMON 86150R107 18,133 -8,397 -31.65 95 -8.65 0.0000
2024-02-12 2023-12-31 13F STOKE THERAPEUTICS COMMON 86150R107 18,133 -8,397 95 0.0000
2023-11-14 2023-09-30 13F STOKE THERAPEUTICS COMMON 86150R107 26,530 3,363 14.52 105 -57.72 0.0000
2023-08-11 2023-06-30 13F STOKE THERAPEUTICS COMMON 86150R107 23,167 -91,300 -79.76 246 -74.21 0.0000
2023-05-18 2023-03-31 13F/A-1 STOKE THERAPEUTICS COMMON 86150R107 114,467 90,608 379.76 954 0.0001
2023-05-11 2023-03-31 13F STOKE THERAPEUTICS COMMON 86150R107 86,327 62,468 811 0.0000
2023-02-13 2022-12-31 13F STOKE THERAPEUTICS COMMON 86150R107 23,859 291 1.23 0 -100.00 0.0000
2022-11-14 2022-09-30 13F STOKE THERAPEUTICS COMMON 86150R107 23,568 1,070 4.76 302 1.68 0.0000
2022-08-11 2022-06-30 13F STOKE THERAPEUTICS COMMON 86150R107 22,498 2,890 14.74 297 -27.91 0.0000
2022-05-11 2022-03-31 13F STOKE THERAPEUTICS COMMON 86150R107 19,608 3,374 20.78 412 5.64 0.0000
2022-02-11 2021-12-31 13F/A-1 STOKE THERAPEUTICS COMMON 86150R107 16,234 1,506 10.23 390 4.00 0.0000
2022-02-10 2021-12-31 13F STOKE THERAPEUTICS COMMON 86150R107 16,234 1,506 390 0.0000
2021-11-12 2021-09-30 13F STOKE THERAPEUTICS COMMON 86150R107 14,728 983 7.15 375 -19.01 0.0000
2021-08-12 2021-06-30 13F STOKE THERAPEUTICS COMMON 86150R107 13,745 4,156 43.34 463 24.13 0.0001
2021-05-12 2021-03-31 13F STOKE THERAPEUTICS COMMON 86150R107 9,589 3,573 59.39 373 0.00 0.0000
2021-02-19 2020-12-31 13F/A-1 STOKE THERAPEUTICS COMMON 86150R107 6,016 1,462 32.10 373 139.10 0.0001
2021-02-11 2020-12-31 13F STOKE THERAPEUTICS COMMON 86150R107 6,016 1,462 373 9.2246
2020-11-12 2020-09-30 13F/A-1 STOKE THERAPEUTICS COMMON 86150R107 4,554 -137 -2.92 156 39.29 0.0000
2020-11-12 2020-09-30 13F STOKE THERAPEUTICS COMMON 86150R107 4,554 156
2020-08-11 2020-06-30 13F STOKE THERAPEUTICS COMMON 86150R107 4,691 -814 -14.79 112 -11.11 0.0000
2020-05-12 2020-03-31 13F STOKE THERAPEUTICS COMMON 86150R107 5,505 2,486 82.35 126 46.51 0.0000
2020-02-11 2019-12-31 13F STOKE THERAPEUTICS COMMON 86150R107 3,019 18 0.60 86 34.38 0.0000
2019-11-12 2019-09-30 13F STOKE THERAPEUTICS COMMON 86150R107 3,001 3,001 64 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-11-12 2020-09-30 13F/A STOKE THERAPEUTICS OPTION Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-08-11 2020-06-30 13F STOKE THERAPEUTICS OPTION Call 8,300 198 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.